	US 12,012,447 B2
	Compositions and methods for reducing at least one symptom of human allergy to cats
Maud Isabelle Lallemand, Beauvais (FR); and Ivan Filipi, St Louis, MO (US)
Assigned to SOCIÉTÉ DES PRODUITS NESTLÉ S.A., Vevey (CH)
Filed by Société des Produits Nestlé S.A., Vevey (CH)
Filed on Apr. 28, 2022, as Appl. No. 17/731,403.
Claims priority of provisional application 63/189,450, filed on May 17, 2021.
Prior Publication US 2022/0363739 A1, Nov. 17, 2022
Int. Cl. A61P 37/08 (2006.01); A61K 47/42 (2017.01); A61K 47/55 (2017.01); C07K 16/18 (2006.01)

CPC C07K 16/18 (2013.01) [A61K 47/42 (2013.01); A61K 47/551 (2017.08); A61P 37/08 (2018.01)]

8 Claims

1. A supplement for reducing allergic response to Fel D1, the supplement comprising dried egg yolk powder comprising an anti-Fel D1 molecule that is anti-Fel D1-specific polyclonal immunoglobulin Y (sIgY), the supplement further comprising a dried animal digest that is thermally-treated meat-based enzymatic hydrolysate,

the dried egg yolk powder is about 1 wt. % to about 30 wt. % of the supplement,

the anti-Fel D1 molecule is about 0.0001 wt. % to about 1 wt. % of the supplement, and

the dried animal digest is about 20 wt. % to about 80 wt. % of the supplement.